Dengue Vaccine - Global Strategic Business Report

The global market for Dengue Vaccine was estimated at US$411.3 Million in 2025 and is projected to reach US$1.0 Billion by 2032, growing at a CAGR of 13.8% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Dengue Vaccine Market - Key Trends and Drivers Summarized

What Is the Dengue Vaccine and How Does It Work Against the Virus?

The dengue vaccine, also known as CYD-TDV or by its commercial name Dengvaxia, is the first vaccine approved for the prevention of dengue disease, caused by the dengue virus. Dengue is transmitted by mosquitoes and is prevalent in tropical and subtropical climates worldwide, affecting millions annually with severe flu-like symptoms and potentially life-threatening complications. The vaccine is a live recombinant tetravalent response to all four virus serotypes, utilizing a weakened version of the yellow fever virus as a vector to express dengue virus proteins. This stimulates the immune system to produce a defense mechanism specifically targeted against the dengue virus if it enters the human body. However, its use is recommended only in populations that are seropositive, meaning they have been previously infected by the virus, as the vaccine can increase the risk of severe dengue in seronegative individuals, those who have never been exposed to the virus.

What Are the Clinical Insights and Public Health Benefits of the Dengue Vaccine?

Clinical trials for the dengue vaccine have shown varied efficacy rates across different serotypes and age groups, with overall efficacy hovering around 60%. The vaccine's effectiveness is notably higher in individuals who have had a previous dengue infection, underscoring its utility in endemic regions where such exposure is common. Public health benefits of the vaccine include reduced hospitalization rates and a decrease in severe dengue cases, which are significant in helping ease the burden on healthcare systems in affected regions. The vaccine is thus considered a critical tool in the fight against dengue, particularly in high-prevalence areas. By reducing the incidence of dengue, it not only saves lives but also reduces economic loss related to healthcare costs and lost productivity due to illness.

What Are the Challenges and Considerations in the Deployment of the Dengue Vaccine?

The deployment of the dengue vaccine has faced several challenges and ethical considerations. One major issue is determining vaccine eligibility, particularly in identifying individuals previously infected by the dengue virus. This requires reliable serological testing, which can be costly and logistically challenging in resource-poor settings. There's also the risk of vaccine-related severe dengue in seronegative vaccine recipients, which has led to controversies and public distrust in some regions following early roll-outs. These challenges necessitate careful planning and public communication strategies to maximize benefits and minimize risks associated with vaccination. Additionally, ongoing research and surveillance are crucial to monitor long-term vaccine safety and effectiveness, especially as the virus evolves and different population dynamics come into play.

What Drives the Growth in the Dengue Vaccine Market?

The growth in the dengue vaccine market is driven by several factors, primarily the high burden of disease in over 100 countries, increasing the demand for effective preventive measures. The expansion of endemic areas due to global warming and increased urbanization, which create ideal breeding conditions for mosquitoes, also spur the need for vaccines. Furthermore, growing international travel continues to introduce dengue into new regions, raising global concern and demand for vaccination. Advances in vaccine technology and increased funding for dengue research have accelerated the development and improvement of dengue vaccines, making them more accessible and affordable. Public-private partnerships and initiatives by global health bodies like the World Health Organization (WHO) to promote vaccination as part of integrated dengue prevention plans also contribute to the growth of the market. These factors, combined with a heightened awareness of the impact of dengue and the availability of preventive options, ensure a dynamic and expanding market for the dengue vaccine.

Report Scope

The report analyzes the Dengue Vaccine market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: End-Use (Government Institutions, Hospitals, NGOs).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Dengvaxia Product segment, which is expected to reach US$479.5 Million by 2032 with a CAGR of 15.9%. The Qdenga Product segment is also set to grow at 13.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $127.2 Million in 2025, and China, forecasted to grow at an impressive 18.8% CAGR to reach $262.5 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Dengue Vaccine Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Dengue Vaccine Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Dengue Vaccine Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as BioNet Asia Co., Ltd., Clayton Biotechnologies, Inc, Codagenix, Inc., Glyden Pharma, GSK Plc and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Dengue Vaccine market report include:

• BioNet Asia Co., Ltd.
• Clayton Biotechnologies, Inc
• Codagenix, Inc.
• Glyden Pharma
• GSK Plc
• ImmuneMed, Inc.
• Instituto Butantan
• Medigen Vaccine Biologics Group
• Meiji Holdings Co., Ltd.
• Merck & Co., Inc.

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 3,602 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.